AACPN welcomes House passage of legislation delaying most federal restrictions on consumable hemp products through December 11, providing Congress additional time to develop a comprehensive regulatory framework.

Originally published in the Hartford Courant, this op-ed examines Connecticut's Public Act 26-108 and its implications for psychedelic-assisted therapy, evidence-based healthcare innovation, and patient access.